Phase I-II trial of acivicin in adult acute leukemia.
Six patients with relapsed or refractory acute leukemia were treated with 9 mg/m2 or 11 mg/m2 of acivicin daily for seven days in a phase I-II trial. No responses were attained and further dose escalation was prohibited by neurotoxicity in 2 of 3 patients who received 11 mg/m2/day. Although acivicin appears to have limited potential as a single agent, laboratory evaluation of leukemic blasts in one patient revealed cell cycle (S-phase accumulation) and metabolic effects which suggest that acivicin may be effective as a modulator of other antileukemia agents such as cytosine arabinoside.
Powell
B L
BL
Oncology Research Center, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, North Carolina.
Craig
J B
JB
Capizzi
R L
RL
Richards
F
F
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D010080:Oxazoles / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D007555:Isoxazoles; D010080:Oxazoles; C006303:acivicin